Hansa Biopharma Balance Sheet Health
Financial Health criteria checks 1/6
Hansa Biopharma has a total shareholder equity of SEK-320.0M and total debt of SEK943.0M, which brings its debt-to-equity ratio to -294.7%. Its total assets and total liabilities are SEK940.7M and SEK1.3B respectively.
Key information
-294.7%
Debt to equity ratio
SEK 942.95m
Debt
| Interest coverage ratio | n/a |
| Cash | SEK 553.54m |
| Equity | -SEK 319.96m |
| Total liabilities | SEK 1.26b |
| Total assets | SEK 940.68m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0RC7 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: 0RC7 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: 0RC7 has negative shareholder equity, which is a more serious situation than a high debt level.
Reducing Debt: 0RC7's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 0RC7 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 0RC7 has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 20.7% each year.